Biology Atlas

Map / Assays

assay · intermediate · partly written

Animal models

Whole animals, most often mouse, used to test safety and efficacy before humans; they keep a body and an immune system and lose human-specific biology.

Also called: mouse models, in vivo animal studies

The short answer

Animals give a whole body with circulation and immunity, but translation to humans is partial and no single rate describes it. See concepts/animal-to-human-translation. 12

Reported, not yet replicated

Their role in the regulatory chain more

FDA guidance sets the first human dose from the no-observed-adverse-effect level in the most appropriate species, converted by body surface area and divided by a safety factor, normally 10. For biologics, ICH S6(R1) defines a relevant species as one in which the test material is pharmacologically active and discourages studies in non-relevant species; relevance starts from target homology and in vitro binding comparison. 34

Reported, not yet replicated

How well they predict the human more

Of 281 therapies with at least 10 years since the first animal study, 5% reached approval and 40% an RCT; 37% of 76 highly cited animal studies replicated in a human RCT; 71% of human toxicities were also seen in animals. Median time from the first animal study to approval was 10 years. These figures count different things. 125

Reported, not yet replicated

Evolutionary distance more

Mouse and human share a common ancestor about 80 million years ago; coding regions average 85% identity, regulation diverges more, and the best-documented mismatches involve the immune system. No opened source measures how much distance explains failure. 678

Reported, not yet replicated

Setting

Where in cascade

Time per run

Median time from the first animal study to any human study, RCT and approval was 5, 7 and 10 years (a pooled lag, not the duration of one study). 1

Reported, not yet replicated

Still open here

Not yet written: Question answered, Readout physical, Not measured, Sample prep, Conditions, Throughput class, Throughput, Cost, Engineerable variants, Use cases, Before after, Capital, Emerging, ML role, Data availability.

Linked from

Sources

  1. Ineichen BV, Furrer E, Grüninger SL, et al.. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLoS Biol (2024). paper; opened 2026-11-17 all records citing this
  2. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA (2006). paper; opened 2026-11-17 all records citing this
  3. US FDA. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. US FDA (2005). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  4. ICH S6(R1): Preclinical safety evaluation of biotechnology-derived pharmaceuticals. International Council for Harmonisation. regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  5. Olson H, Betton G, Robinson D, et al.. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol (2000). paper; opened 2026-11-17 all records citing this
  6. Importance of the mouse genome (NHGRI page, updated 2010). NHGRI (2010). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
  7. Yue F, Cheng Y, Breschi A, et al.. A comparative encyclopedia of DNA elements in the mouse genome. Nature (2014). paper; opened 2026-11-17 all records citing this
  8. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol (2004). review; opened 2026-11-17 all records citing this
History of this record (1)

This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Status
partly written
Last updated
2026-11-17
Record
content/assays/animal-models.json